The CYP3A422 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients

Tacrolimus, a dual substrate of CYP3A4 and CYP3A5 has a narrow therapeutic index and is characterized by high between-subject variability in oral bioavailability. This study investigated the effects of the recently described CYP3A4*22 intron 6 C>T single nucleotide polymorphism on in vivo CYP3A4...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The pharmacogenomics journal 2015-04, Vol.15 (2), p.144-152
Hauptverfasser:	de Jonge, H, Elens, L, de Loor, H, van Schaik, R H, Kuypers, D R J
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/575 Alleles Bioavailability Biomedical and Life Sciences Biomedicine Cross-Sectional Studies Cytochrome P-450 CYP3A - genetics Dosage and administration Drug metabolism Female Gene Expression Gene polymorphism Genetic aspects Genotype Health aspects Human Genetics Humans Kidney Transplantation Kidneys Male Midazolam Midazolam - pharmacokinetics Middle Aged Oncology original-article Pharmacokinetics Pharmacotherapy Polymorphism Polymorphism, Single Nucleotide - genetics Psychopharmacology Single nucleotide polymorphisms Single-nucleotide polymorphism Tacrolimus Tacrolimus - pharmacokinetics Transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!